Precigen, Inc. (PGEN) Stock Forecast
Data as of Aug 6, 2026Healthcare · Current price $6.79 (-1.38%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
PGEN vs Sector & Market
| Metric | PGEN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 7 | 8 | 18 |
| Target Upside | +125.8% | +16316.0% | +17.2% |
| P/E Ratio | -5.02 | 3.22 | 35.79 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $26M | $31M | $38M | 1 |
| 2026-12-31 | $31M | $37M | $45M | 1 |
| 2027-12-31 | $191M | $209M | $227M | 2 |
| 2028-12-31 | $266M | $320M | $372M | 1 |
| 2029-12-31 | $363M | $436M | $507M | 1 |
| 2030-12-31 | $483M | $580M | $675M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2026-12-31 | $0.01 | $0.01 | $0.01 | 1 |
| 2027-12-31 | $0.12 | $0.15 | $0.18 | 2 |
| 2028-12-31 | $0.34 | $0.44 | $0.53 | 1 |
| 2029-12-31 | $0.54 | $0.69 | $0.84 | 1 |
| 2030-12-31 | $0.80 | $1.02 | $1.24 | 1 |
Frequently Asked Questions
What is the analyst consensus for PGEN?
The consensus among 7 analysts covering Precigen, Inc. (PGEN) is Buy with an average price target of $14.00.
What is the highest price target for PGEN?
The highest analyst price target for PGEN is $14.00.
What is the lowest price target for PGEN?
The lowest analyst price target for PGEN is $14.00.
How many analysts cover PGEN?
7 analysts have issued ratings for Precigen, Inc. in the past 12 months.
Is PGEN a buy or sell right now?
Based on 7 analyst ratings, PGEN has a consensus rating of Buy (2.00/5) with a +125.8% upside to the consensus target of $14.00.
What are the earnings estimates for PGEN?
Analysts estimate PGEN will report EPS of $-0.01 for the period ending 2026-09-30, with revenue estimated at $31M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.